Harbor Capital Advisors Inc. Sells 22,228 Shares of Haemonetics Corporation $HAE
Harbor Capital Advisors Inc. significantly reduced its stake in Haemonetics Corporation (NYSE:HAE) by 51.9%, selling 22,228 shares and retaining 20,631 shares valued at $1.654 million. This move comes as other large investors either increased or initiated positions in Haemonetics. The company recently exceeded Q4 earnings expectations with $1.31 EPS and provided optimistic FY2026 guidance, maintaining a "Moderate Buy" consensus rating and an average price target of $83.89.
HAE PE Ratio & Valuation, Is HAE Overvalued
Haemonetics Corp (HAE) is currently considered undervalued, with a forward PE ratio of 10.32 compared to its five-year average of 19.59. Its fair price is estimated to be between $87.10 and $134.17, making it undervalued by 34.75% relative to its current price of $56.83. The article also provides current P/B ratio, FCF yield, and P/S ratio, comparing them against historical averages and competitor benchmarks.
Haemonetics will post earnings at 6 a.m., then take questions at 8
Haemonetics (NYSE: HAE) announced it will release its fourth quarter and fiscal year 2026 financial results on May 7, 2026, at 6:00 am ET. This will be followed by a conference call for investors and analysts at 8:00 am ET on the same day. A live webcast and replay will be available on the company's investor relations website, maintaining its consistent pattern of advance earnings-date notices.
Allspring Global Investments Holdings LLC Sells 121,063 Shares of Haemonetics Corporation $HAE
Allspring Global Investments Holdings LLC reduced its stake in Haemonetics Corporation (NYSE:HAE) by 11.4% in the fourth quarter, selling 121,063 shares. Despite this, Haemonetics' stock is rated a "Moderate Buy" with a consensus price target of $83.89, and the company recently beat earnings estimates and provided strong FY2026 guidance. Institutional investors collectively own 99.67% of the company's stock.
Is Haemonetics (HAE) Leveraging VASCADE MVP XL’s FDA Expansion To Deepen Its EP Moat?
Haemonetics recently received FDA approval to expand the labeling for its VASCADE MVP XL venous vascular closure system, allowing it to be used with larger procedural sheaths in advanced electrophysiology procedures. This expansion, supported by clinical trial data, strengthens Haemonetics' position in the electrophysiology market. While this development offers fresh regulatory support and an improved investment narrative, the article cautions that competitive pressure, reliance on U.S.-centric franchises, and operational challenges remain key concerns for investors.
Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System
Haemonetics Corporation announced FDA approval for expanded labeling of its VASCADE MVP® XL venous vascular closure system. This expansion allows the system to be used with larger procedural sheaths (10-14F ID, up to 17F OD), supporting market-leading technologies for pulsed field ablation (PFA) and left atrial appendage closure (LAAC) in atrial fibrillation treatment. Clinical trials demonstrated 0% major and minor access site complications and a median time to ambulation of 2.4 hours.
FDA expands use of Haemonetics device in atrial fibrillation care
Haemonetics (NYSE: HAE) received FDA approval to expand the labeling for its VASCADE MVP® XL venous vascular closure system, allowing its use with larger procedural sheaths (10-14F inner diameter and up to 17F outer diameter). This expansion broadens the device's applicability to procedures like pulsed field ablation (PFA) and left atrial appendage closure (LAAC) for atrial fibrillation, supported by clinical trials showing 0% major complications. The company anticipates this will accelerate commercial strategy and support a wider range of procedures in hospitals and surgical centers.
Haemonetics Corp. Experiences Revision in Stock Evaluation Amid Market Challenges
Haemonetics Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, is facing significant challenges with substantial stock performance declines over the past one and five years. Technical indicators show a bearish sentiment, reflecting difficulties in regaining market traction against broader market trends. The company's stock closed at $54.04, down from $55.52, with a -15.84% return over the past year compared to the S&P 500's 11.87% gain.
Short Interest in Haemonetics Corporation (NYSE:HAE) Decreases By 29.7%
Haemonetics Corporation (NYSE:HAE) experienced a significant decrease in short interest, falling by 29.7% to 1,904,947 shares as of March 13th. Institutional investors now own approximately 99.67% of the stock, with several large firms increasing their stakes. Despite recent analyst price target reductions, the company holds a "Moderate Buy" consensus rating and recently beat earnings estimates with strong FY2026 EPS guidance.
Assenagon Asset Management S.A. Sells 99,083 Shares of Haemonetics Corporation $HAE
Assenagon Asset Management S.A. reduced its stake in Haemonetics Corporation by 56.4% in the fourth quarter of the prior year, selling 99,083 shares but still holding 76,491 shares valued at approximately $6.13 million. Despite this sale, other institutional investors increased their holdings in the medical instruments supplier. Haemonetics demonstrated strong financial performance, surpassing quarterly EPS and revenue estimates and providing an optimistic FY2026 outlook.
Vanguard disaggregates holdings after internal realignment (NYSE: HAE)
The Vanguard Group filed an amended Schedule 13G/A, reporting 0 shares and 0% beneficial ownership of Haemonetics Corp (HAE) common stock. This change is due to an internal realignment on January 12, 2026, which causes certain Vanguard subsidiaries to report their ownership separately, as per SEC Release No. 34-39538. The filing is administrative, reflecting a change in reporting structure rather than an economic transaction.
A Look At Haemonetics (HAE) Valuation After Recent Share Price Weakness
Haemonetics (HAE) shares have experienced significant weakness over the past three months, but the company is considered undervalued with a fair value estimate of $88.00 against its current price of $55.93. This valuation is largely driven by strong performance in its plasma and hospital technologies segments, including rapid innovation and increased adoption of advanced plasma collection systems. Investors are encouraged to review the full narrative and assess the risks and growth profile to determine if the sustained weakness presents a potential entry point.
HAE Price Today: Haemonetics Corporation Stock Price, Quote & Chart
This article provides a current stock quote and chart for Haemonetics Corporation (HAE), detailing its recent price changes, market data, and company information. It also includes instructions on how to buy HAE stock on MEXC and answers frequently asked questions about its financial performance and classification. The company operates in the surgical & medical instruments & apparatus sector, focusing on blood and plasma component collection.
Haemonetics Corp stock faces uncertainty amid lack of fresh catalysts in blood management sector
Haemonetics Corp (US4041191090) stock is in a holding pattern on the NYSE due to a lack of recent catalysts, despite its leadership in blood management solutions. The company's revenue heavily relies on recurring disposable sales from its plasma and blood center segments. US investors should monitor hospital budgets and plasma market volumes, as Haemonetics remains a watch-list candidate for those seeking stability and growth potential in healthcare innovation.
Haemonetics Corp stock faces uncertainty amid lack of fresh catalysts in blood management sector
Haemonetics Corp stock is currently in a holding pattern due to a lack of fresh catalysts in the blood management sector, despite steady demand for its plasma collection and transfusion technologies. The company, a leader in automated blood processing, benefits from recurring disposable sales in its Plasma and Blood Center segments. Investors should consider the company's solid financial health and
Hospital Solutions launch from Haemonetics aims to transform patient care standards
Haemonetics has launched its new Hospital Solutions, leveraging over fifty years of healthcare experience to improve procedural effectiveness and patient experience. These tailored approaches emphasize innovation and expertise, encouraging healthcare providers to adopt them for enhanced clinical outcomes. The company is actively recruiting for clinical support roles to further boost operational capacity and patient care.
Haemonetics Corp Stock Surges on Strong Momentum Amid Plasma and Hemostasis Demand
Haemonetics Corp (HAE) has seen its stock surge by 59.25%, driven by strong demand in blood management, plasma collection, and hemostasis products. The company's innovative medical devices and integrated IT platforms are key contributors to its robust performance in the healthcare sector. Investors are keenly awaiting the upcoming Q3 fiscal 2025 results for further insights into its growth trajectory and efforts to manage global supply chain shifts.
Haemonetics Corp Stock Surges on Strong Momentum Amid Plasma and Hemostasis Demand
Haemonetics Corp (HAE) stock has surged by 59.25%, driven by strong demand in plasma collection and hemostasis management. The company's robust product portfolio and global leadership in blood management solutions position it favorably in the medical device sector. US investors are particularly watching the upcoming Q3 fiscal 2025 results for further catalysts and insights into its sustained momentum.
What Investors Need to Understand About a $24 Million Sale in a Medical Device Stock That Has Fallen 9% Over the Past Year
Invenomic Capital Management has sold its entire $24 million stake in Haemonetics Corporation (NYSE:HAE), a medical device company specializing in blood and plasma management. This divestment follows a period of volatile performance for Haemonetics, which saw its stock fall 9% over the past year despite a surge after strong Q3 results, subsequently giving back 27% of those gains this year. While the company's revenue growth has become more complex due to divestitures and changing product mix, profitability has improved with rising gross margins and operating income.
What Investors Need to Understand About a $24 Million Sale in a Medical Device Stock That Has Fallen 9% Over the Past Year
Invenomic Capital Management has fully divested its $24.29 million stake in Haemonetics Corporation (NYSE:HAE), a medical device company specializing in blood and plasma management. This sale occurred after Haemonetics shares surged nearly 70% in the previous quarter but have since dropped 27% this year, contributing to a 9% decline over the past year. While Haemonetics is facing challenges like inconsistent performance and divestitures, its profitability is improving with rising gross margins and operating income.
Haemonetics Corp. Forms Death Cross, Signaling Potential Bearish Trend Ahead
Haemonetics Corp. has experienced a Death Cross, a technical indicator suggesting a potential bearish trend. The company faces significant challenges, including a 8.94% decline over one year and a 26.51% year-to-date drop, contrasting sharply with the S&P 500's performance. Technical indicators like MACD and Bollinger Bands also point to a bearish outlook, prompting investors to monitor these trends closely.
Here's why Haemonetics (HAE) is a strong value stock
This article from MSN discusses why Haemonetics (HAE) is considered a strong value stock. It likely delves into various financial metrics and company specific data to support this claim, positioning HAE as a potential investment opportunity for value-oriented investors. The analysis would aim to highlight the intrinsic value of the company compared to its current market price.
Here's why Haemonetics (HAE) is a strong value stock
This article from MSN discusses why Haemonetics (HAE) is considered a strong value stock. It likely delves into financial metrics, market position, or future growth prospects that make HAE an attractive investment based on value principles. Potential topics could include its P/E ratio, earnings, or industry standing.
Haemonetics Corporation (HAE) Q3 performance prompts Baird model update, price target falls to $81
Baird has adjusted its financial model for Haemonetics Corporation following the company's third-quarter earnings report. Despite Q3 results largely meeting expectations, Baird lowered its price target for HAE to $81, down from the previous $86. This revision is attributed to a slightly reduced fiscal year 2024 guidance and updated estimates for fiscal years 2025 and 2026.
London Co. of Virginia Decreases Stake in Haemonetics Corporation $HAE
London Co. of Virginia reduced its stake in Haemonetics Corporation (NYSE:HAE) by 7.1% in the third quarter, now holding 266,034 shares valued at approximately $12.97 million. Haemonetics recently reported strong Q3 earnings, beating EPS estimates, and provided positive FY2026 guidance. Wall Street maintains a "Moderate Buy" rating for the company, with institutional investors owning a significant 99.67% of the stock.
Haemonetics Corporation (HAE) Stock Price Prediction for 2026, 2030-2040
This article provides a detailed stock price prediction for Haemonetics Corporation (HAE) for 2026, and extends forecasts to 2030-2040, alongside market cap history and analyst consensus ratings. It presents monthly price ranges for 2026 and quarterly/annual EPS and revenue forecasts. The prediction methodology combines technical indicators, statistical modeling, and expert insights from leading investment institutions.
Is Haemonetics (HAE) Quietly Rewiring Its Margin Profile Through NexSys PCS And Hospital Acquisitions?
Haemonetics (HAE) is reportedly improving its operational efficiency and deepening its role in critical care through the growing adoption of its FDA-approved NexSys PCS system with Persona Technology and strategic hospital acquisitions. While this recovery in the Hospital division supports some investment theses, the company's high debt load remains a key concern for analysts. Despite cautious ratings from some, the momentum from NexSys and hospital growth could significantly impact Haemonetics' future financial performance and investor expectations.
Haemonetics Corporation (NYSE:HAE) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Haemonetics Corporation (NYSE:HAE) has received a consensus recommendation of "Moderate Buy" from eleven analysts, with an average 12-month price target of $83.89. The company recently exceeded quarterly earnings and revenue estimates and provided strong FY 2026 guidance. Institutional investors hold a significant majority of the stock, which is currently trading around $59.93 with a P/E ratio of 16.5.
Haemonetics Corp Stock (ISIN: US4041191090) Faces Pressure Amid Hospital Recovery and Debt Concerns
Haemonetics Corp's stock has declined sharply in 2026, down over 34% year-to-date, due to high debt levels overshadowing gains in its hospital segment driven by the NexSys PCS system. Despite challenges, the company's Hospital division is recovering, and analyst targets suggest significant upside potential, attracting patient European investors. The company maintains a "Moderate Buy" consensus rating and solid profitability, but debt reduction remains a key priority for shareholder returns.
Haemonetics Expands Hospital Portfolio As Investors Weigh Growth And Valuation
Haemonetics (NYSE:HAE) is expanding its Hospital division by transitioning to its NexSys PCS system for plasma collection and acquiring Attune Medica and OpSens, which add capabilities in hospital and interventional cardiology. This strategic shift aims to broaden its market footprint, but investors should monitor product integration, hospital adoption, and the company's debt levels. Despite the new growth initiatives, the stock is currently trading significantly below analyst targets and its estimated fair value.
Haemonetics Corp Stock (ISIN: US4041191090) Expands Hospital Portfolio Amid Valuation Discount and A
Haemonetics Corp is expanding its hospital division through the NexSys PCS system and strategic acquisitions like Attune Medica and OpSens. Despite a significant discount compared to analyst targets and a recent price target cut by Citi, the company aims for diversified growth beyond plasma collection. The article highlights Haemonetics' shift towards higher-margin consumables and integrated solutions, emphasizing careful monitoring of adoption rates and financial health due to elevated debt from acquisitions.
Haemonetics Corp. Experiences Revision in Its Stock Evaluation Amid Market Dynamics
Haemonetics Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has revised its stock evaluation metrics. The company currently shows a P/E ratio of 15 and a price-to-book value of 2.77, maintaining a favorable valuation compared to peers despite a year-to-date return of -25.78%. Key financial indicators include an EV to EBIT of 14.96, EV to EBITDA of 9.90, a PEG ratio of 1.12, ROCE of 12.44%, and ROE of 18.06%.
A Look At Haemonetics (HAE) Valuation After Recent Share Price Weakness
Haemonetics (HAE) has experienced recent stock price declines, with a 7.4% drop over the past week and a 28.7% decline over three months, raising questions about its valuation. Despite this, a common narrative suggests the stock is 32.4% undervalued, with a fair value of US$88.00 due to strategic portfolio transformation and margin expansion. However, the company faces risks, including reliance on specific products and execution challenges with new integrations.
Is Keeping Haemonetics Stock in Your Portfolio a Wise Choice at This Time?
Haemonetics Corporation (HAE) is showing strong recovery in its Hospital division, driven by the NexSys PCS system's adoption, despite facing challenges like high debt and intense competition. The company has consistently exceeded earnings expectations, and its stock performance has been better than the broader medical products sector. While analyst estimates for fiscal 2026 remain steady, financial leverage is a concern, prompting investors to consider alternatives in the medical sector.
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
Haemonetics' stock performance has lagged, but its Hospital business shows recovery driven by acquisitions and strong blood management technologies. The NexSys PCS system's adoption is also a key growth driver. However, the company faces concerns due to a debt-heavy balance sheet and a highly competitive market within the medical space.
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
Haemonetics (HAE) is poised for growth due to the recovery of its Hospital business and the strong adoption of its NexSys PCS system. However, the company faces concerns regarding its debt-burdened balance sheet and competitive market pressures. Despite these challenges, Haemonetics has a history of beating earnings estimates, and Zacks Equity Research suggests other medical stocks like Globus Medical, Intuitive Surgical, and Edwards Lifesciences as strong buys.
Haemonetics Corporation $HAE Shares Acquired by Barrow Hanley Mewhinney & Strauss LLC
Barrow Hanley Mewhinney & Strauss LLC significantly increased its stake in Haemonetics Corporation (NYSE:HAE) by 16.5% in the third quarter, adding 79,138 shares to hold a total of 559,972 shares valued at $27.29 million. Haemonetics reported strong quarterly earnings, beating analyst expectations with an EPS of $1.31 and revenue of $338.97 million, and has a "Moderate Buy" consensus rating with an average price target of $83.89. The company's stock opened at $60.69, reflecting a 3.4% dip, and institutional investors own nearly all of its shares at 99.67%.
Citigroup Maintains Neutral Rating on Haemonetics (HAE), Lowers Price Target | HAE Stock News
Citigroup analyst Joanne Wuensch maintained a 'Neutral' rating on Haemonetics (HAE) and lowered the price target from $75.00 to $70.00, a 6.67% decrease. This adjustment follows other recent analyst updates, including both reiterations of 'Buy' and 'Outperform' ratings, and some price target adjustments both up and down for HAE. Haemonetics, which focuses on medical products for blood and plasma collection, surgical suites, and hospital transfusion services, currently has an average target price of $88.00 from 10 analysts, suggesting an upside of 46.70% from its current price.
Citigroup Issues Pessimistic Forecast for Haemonetics (NYSE:HAE) Stock Price
Citigroup has lowered its price target for Haemonetics (NYSE:HAE) from $75 to $70, maintaining a "neutral" rating, which implies a 16% upside from the current share price. This comes despite Haemonetics slightly beating quarterly EPS and revenue estimates, though revenue was down 2.7% year-over-year. The medical instruments supplier's stock fell by about 4% to $60.33 midday, contrasting with an analyst consensus of "Moderate Buy" and an average target price of $83.89.
Haemonetics Gets FDA Clearance for NexSys PCS System
Haemonetics Corporation received FDA 510(k) clearance for its NexSys PCS Plasma Collection System with Persona PLUS technology. This system is designed to enhance the efficiency and safety of plasma collection, allowing for higher average plasma volumes per session and optimized workflow. The approval strengthens Haemonetics' competitive position and helps address the increasing demand for plasma-derived therapies in the U.S. market.
Haemonetics launches recruitment drive to expand clinical support roles
Haemonetics is actively recruiting professionals for clinical support roles to enhance patient outcomes and strengthen relationships within the healthcare field. The company is seeking talent committed to making a tangible difference, with specific job details available on its careers portal. This initiative highlights Haemonetics' focus on collaboration and clinical support expansion.
HAE SEC Filings - Haemonetics Corp Mass 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Haemonetics Corporation's SEC filings, including 10-K annual reports, 10-Q quarterly earnings, and 8-K material events. It details how investors can use these filings to understand financial results, acquisition terms, and shareholder matters, with recent examples such as the acquisition of Vivasure Medical Limited and executive insider stock sales. The platform also offers AI-powered tools to summarize and highlight key information within these regulatory documents.
Haemonetics Wins FDA Nod For Persona PLUS Plasma Growth Opportunity
Haemonetics (NYSE:HAE) received FDA 510(k) clearance for its NexSys PCS Plasma Collection System with Persona PLUS technology. This new platform is designed to improve plasma collection per donation, offering a mid-single-digit percentage increase in plasma volume. The clearance positions Haemonetics competitively in the plasma collection market and could drive future growth, though investors should consider risks like debt levels and reliance on a few key products.
A Look Back at Medical Devices & Supplies - Specialty Stocks' Q4 Earnings: Haemonetics (NYSE:HAE) Vs The Rest Of The Pack
This article reviews the Q4 earnings performance of specialty medical devices and supplies stocks, focusing on Haemonetics (NYSE:HAE) in comparison to its peers. It highlights the mixed results across the sector, with Haemonetics reporting slowing revenue growth despite beating estimates, while Globus Medical (NYSE:GMED) showed strong performance and STAAR Surgical (NASDAQ:STAA) delivered the weakest results against analyst expectations. The broader market context, including inflation and interest rate changes, is also discussed.
Haemonetics Corporation $HAE Shares Sold by Fisher Asset Management LLC
Fisher Asset Management LLC recently reduced its stake in Haemonetics Corporation (NYSE:HAE) by 3.9%, selling 26,638 shares but still holding 662,504 shares valued at approximately $32.3 million. Despite this, institutional investors collectively own 99.67% of the company's stock. Haemonetics surpassed Q3 earnings estimates with an EPS of $1.31 and revenue of $338.97 million, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $84.44.
Haemonetics Retires 2026 Convertible Notes, Simplifies Capital Structure
Haemonetics (HAE) fully repaid its outstanding 0.00% Convertible Senior Notes due 2026, totaling $300 million in cash. This action simplifies the company's capital structure by removing convertible debt and reducing potential future equity dilution. Analysts currently rate HAE as a Buy with an $88.00 price target, although TipRanks’ AI Analyst, Spark, assigns a Neutral rating due to weak technicals but acknowledges strong cash generation and reasonable valuation.
Haemonetics repays $300 million convertible notes at maturity
Haemonetics Corporation announced the full repayment of its $300 million 0.00% Convertible Senior Notes due March 2, utilizing cash on hand and its revolving credit facility. No noteholders exercised conversion rights prior to maturity. This news follows the company's strong Q3 fiscal 2026 results and FDA clearance for its NexSys PCS Plasma Collection System.
3 Reasons HAE is Risky and 1 Stock to Buy Instead
This article analyzes Haemonetics (HAE), highlighting three reasons why it is considered risky: slow organic growth suggesting waning demand in its core business, limited distribution channels due to its small size in a scale-driven industry, and a history of unimpressive capital efficiency in growth initiatives. Despite its recent stock performance, the author suggests investors look for more exciting opportunities, proposing a more dominant software business as an alternative investment.
Haemonetics Corporation (HAE) Stock Analysis: Exploring A 37.76% Potential Upside
This article analyzes Haemonetics Corporation (HAE), highlighting its market position in medical devices, strong financial metrics, and positive analyst outlook. The company shows a potential upside of 37.76%, driven by its innovative products for blood plasma collection and critical care sectors. Despite no dividend payouts, its reinvestment strategy and robust free cash flow suggest long-term shareholder value.
Haemonetics Corp repays outstanding 0.00% convertible senior notes - SEC filing
Haemonetics Corporation has repaid its outstanding 0.00% convertible senior notes, as reported in an SEC filing. This news was published on March 3, 2026, at 8:38 am EST. The company, a global healthcare firm specializing in medical products for blood and plasma collection, surgical suites, and hospital transfusion services, continues to manage its financial obligations.
